Collegium Pharmaceutical Inc (NASDAQ:COLL) Sellers Covered 8.61% of Their Shorts

The stock of Collegium Pharmaceutical Inc (NASDAQ:COLL) registered a decrease of 8.61% in short interest. COLL’s total short interest was 2.62 million shares in May as published by FINRA. Its down 8.61% from 2.87M shares, reported previously. With 403,100 shares average volume, it will take short sellers 7 days to cover their COLL’s short positions.

The stock decreased 4.34% or $0.64 during the last trading session, reaching $14.12. About 352,588 shares traded. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has declined 24.57% since May 12, 2018 and is downtrending. It has underperformed by 28.94% the S&P500.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The company has market cap of $471.21 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain. It currently has negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

Among 3 analysts covering Collegium Pharmaceutical (NASDAQ:COLL), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Collegium Pharmaceutical had 9 analyst reports since February 22, 2019 according to SRatingsIntel. As per Friday, March 15, the company rating was maintained by Cantor Fitzgerald. Cantor Fitzgerald maintained it with “Buy” rating and $35 target in Friday, March 8 report. As per Friday, March 22, the company rating was maintained by Cantor Fitzgerald. Cantor Fitzgerald maintained the shares of COLL in report on Friday, February 22 with “Buy” rating. The company was initiated on Tuesday, March 19 by SunTrust. H.C. Wainwright maintained the shares of COLL in report on Monday, March 4 with “Buy” rating.

More notable recent Collegium Pharmaceutical, Inc. (NASDAQ:COLL) news were published by: Seekingalpha.com which released: “Summers Value Partners Q3 Investor Letter – Seeking Alpha” on October 17, 2018, also Seekingalpha.com with their article: “Axsome Therapeutics leads healthcare gainers; La Jolla Pharmaceutical and ContraFect among losers – Seeking Alpha” published on January 07, 2019, Globenewswire.com published: “Market Trends Toward New Normal in Pareteum, Discovery Communications, Midstates Petroleum, Watsco, Collegium Pharmaceutical, and Cross Country Healthcare — Emerging Consolidated Expectations, Analyst Ratings – GlobeNewswire” on April 08, 2019. More interesting news about Collegium Pharmaceutical, Inc. (NASDAQ:COLL) were released by: Nasdaq.com and their article: “ITV to team up with BBC in ‘BritBox’ subscription streaming offer – Nasdaq” published on February 27, 2019 as well as Nasdaq.com‘s news article titled: “Occidental Announces Dividend – Nasdaq” with publication date: May 09, 2019.